The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Mar. 01, 2018
Applicant:

Theripion, Inc., Shoreline, WA (US);

Inventors:

Martha S. Hayden-Ledbetter, Shoreline, WA (US);

Jeffrey A. Ledbetter, Shoreline, WA (US);

Assignee:

Theripion, Inc., Shoreline, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/775 (2006.01); C07K 19/00 (2006.01); C12N 9/18 (2006.01); C12N 9/22 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/775 (2013.01); C12N 9/18 (2013.01); C12N 9/22 (2013.01); C12N 15/62 (2013.01); C12Y 301/01002 (2013.01); C12Y 301/01047 (2013.01); C12Y 301/08001 (2013.01); C07K 2319/30 (2013.01); C12Y 301/27005 (2013.01);
Abstract

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.


Find Patent Forward Citations

Loading…